Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation

JOACHIM HAVLA, PETER LOHSE, LISA ANN GERDES, REINHARD HOHLFELD, and TANIA KÜMPFEL

ABSTRACT. Objective. Tumor necrosis factor (TNF) receptor 1–associated periodic syndrome (TRAPS) is an autoinflammatory disorder caused by autosomal dominantly inherited mutations in the TNF receptor superfamily 1A (*TNFRSF1A*) gene. The D12E substitution has been described only once to date, in a 4-year-old boy with fever.

Methods. For DNA sequence analysis of the *TNFRSF1A* gene, genomic DNA was isolated, amplified by PCR, purified, and sequenced.

Results. We describe 3 families (8 subjects) with the TNFRSF1A D12E substitution and TRAPS-related symptoms, in 4 cases associated with the autoimmune diseases multiple sclerosis and rheumatoid arthritis.

Conclusion. The clinical phenotype might be associated with the TNFRSF1A D12E mutation. There is a close pathophysiological relationship between TNF signaling and autoimmune disorders. (J Rheumatol First Release Jan 15 2013; doi:10.3899/jrheum.120729)

Key Indexing Terms:

TNF RECEPTOR SUPERFAMILY 1A GENE RHEUMATOID ARTHRITIS PHENOTYPE TNF RECEPTOR 1–ASSOCIATED PERIODIC SYNDROME GENOTYPE MULTIPLE SCLEROSIS

Tumor necrosis factor receptor 1-associated periodic syndrome (TRAPS) is an autosomal dominantly inherited autoinflammatory disorder caused mainly by mutations in exons 2, 3, 4, or 6 of the tumor necrosis factor (TNF) receptor superfamily 1A (TNFRSF1A) gene located on chromosome 12p13, which encodes the 55-kDa receptor for TNF- $\alpha^{1,2}$. TRAPS is characterized by recurrent, self-limiting attacks of fever, abdominal pain, myalgia, rash,

From the Institute of Clinical Neuroimmunology and the Department of Clinical Chemistry, Ludwig-Maximilians University, Munich, Germany.

Dr. Hohlfeld is supported by the Deutsche Forschungsgemeinschaft (SFB 571) and has received personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, Biogen-Idec, and Novartis. Dr. Havla and Dr. Gerdes have received travel expenses and personal compensation from Merck-Serono, TEVA, Bayer-Schering, Novartis, and Biogen-Idec. Dr. Kümpfel has received travel expenses and personal compensation from Bayer-Schering Pharmacy, TEVA, Merck-Serono, and Biogen-Idec as well as grant support from Bayer-Schering AG.

J. Havla, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University; P. Lohse, MD, Department of Clinical Chemistry, Ludwig-Maximilians University, currently at the Institut of Laboratory Medicine and Human Genetics, Singen, Germany; L.A. Gerdes, MD; R. Hohlfeld, MD; T. Kümpfel, MD, Institute of Clinical Neuroimmunology, Ludwig-Maximilians University.

Address correspondence to Dr. T. Kümpfel, Institute of Clinical Neuroimmunology, Campus Grosshadern Ludwig-Maximilians University, Marchioninistr. 15, D-81377 Munich, Germany. E-mail: tania.kuempfel@med.uni-muenchen.de

Accepted for publication November 27, 2012.

arthralgia/arthritis, and rhinolaryngeal involvement with pharyngitis, as well as conjunctivitis and periorbital edema. More than 80 different *TNFRSF1A* mutations with a heterogeneous symptom spectrum have been identified to date^{3,4}. The D12E substitution is a missense mutation that has been described only once to date, in a 4-year-old boy who experienced up to 60 fever episodes per year of 3 days' duration each since the age of 1 year⁵. We describe 3 additional index cases and 5 family members also carrying the D12E exchange in heterozygous form.

MATERIALS AND METHODS

All individuals were seen in our outpatient clinic at the Institute for Clinical Neuroimmunology in Munich, Germany. All subjects/parents gave their written informed consent prior to the genetic testing, according to the Declaration of Helsinki. For DNA sequence analysis of the *TNFRSF1A* gene, genomic DNA was isolated, amplified by PCR, purified, and sequenced.

RESULTS

We identified 3 index cases and 5 additional family members who were heterozygous for the D12E/p.Asp41Glu substitution encoded by exon 2 of the *TNFRSF1A* gene. Clinical characteristics are shown in Table 1 and Figure 1. Seven of the 8 subjects (87.5%) presented with typical TRAPS-related health problems. The leading symptoms were arthralgias/arthritis (75%), followed by abdominal

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2013. All rights reserved.

Table 1. Clinical characteristics of the mutation-positive patients.

Patient No. and Origin	Sex	Age, yrs	Episodes with TRAPS-related Symptoms	Acute-phase Response Markers	Autoimmune Disease	Family History	Therapy
IP1							
German	F	22	Arthralgias, migraine, mild fever episodes, fatigue	Intermittent elevation of TNF- α , ESR, CRP, SAA	RRMS	Pos	NSAID
F1							
German S1.1	M	50	Migraine, fatigue	NK	RRMS		None
German	F	19	Arthralgias, abdominal pain, bifrontal headaches	Intermittent elevation of TNF-α, CRP, SAA	None		NSAID
S1.2							
German	F	9	Abdominal pain	Intermittent elevation of CRP, ESR, SAA	None		None
B1							
German IP2	M	11	Arthralgias	ESR elevation	None		None
Austrian	F	28	Arthralgias, arthritis, abdominal pain, diarrhea, conjunctivitis	Intermittent elevation of CRP, ESR, SAA, TNF-α, IL-6, RF-positive	RA, RRMS	Pos	NSAID, oral steroids, MTX, LEF
D2			3				
Austrian	F	8	Arthralgias, abdominal pain, diarrhea	NK	None		None
IP3			F,				
German	F	37	Arthralgias, myalgias, eyelic edema, bifrontal headaches, abdominal pain, fatigue		RRMS	Pos*	NSAID, oral steroids, glatiramer acetate (for RRMS)

^{*} Index patient 3 family history with RA in 1 grandmother, 2 sisters with arthralgias, 1 sister with possible MS. IP: index patient; F: father; S: sister; B: brother; D: daughter (for example, S1.1 = first sister of index patient 1); CRP: C-reactive protein; SAA: serum amyloid A; ESR: erythrocyte sedimentation rate; RF: rheumatoid factor; IL-6: interleukin 6; TNF- α : tumor necrosis factor; RRMS: relapsing-remitting multiple sclerosis; RA: rheumatoid arthritis; NK: not known; NSAID: nonsteroidal antiinflammatory drug.





Figure 1. DNA sequence electropherograms of TNF receptor superfamily 1A exon 2 from a control (left) and index Patient 2 (right).


pain (50%). In 6 patients, laboratory testing was available and showed an intermittent elevation of acute-phase response markers in 5 of them. In 4 of our 8 patients, concomitant autoimmune diseases were present [4 with the

relapsing-remitting form of multiple sclerosis (RRMS) and 1 with additional rheumatoid arthritis (RA); Figure 2]. Index patient 3 also tested positive for a heterozygous, combined P369S/R408Q mutation encoded by exon 3 of the *MEFV*

 $Personal\ non-commercial\ use\ only.\ The\ Journal\ of\ Rheumatology\ Copyright\ @\ 2013.\ All\ rights\ reserved.$










Figure 2. Joint destruction in index case 2.

gene. Because her symptoms (arthralgias/arthritis, myalgias) responded to steroid but not to colchicine therapy, her rheumatological symptoms were attributed to the TNFRSF1A D12E mutation.

Through genetic analyses in > 3000 patients with symptoms suggestive of an autoinflammatory disease, this alteration was detected to date in only 5 individuals, including the 3 index patients presented here (P. Lohse, unpublished observations). This argues against D12E being a common variant. Other exchanges were not observed at this amino acid position.

DISCUSSION

To our knowledge, there is only 1 patient with a TNFRSF1A D12E substitution and TRAPS-related fever described to date⁵. We described another 3 index cases as well as 5 additional family members carrying the D12E substitution, 7 of them presenting with TRAPS-related symptoms [mainly arthritis/arthralgia, diarrhea, and/or abdominal pain (Table 1)]. Overall, the phenotypes were mild with only slight elevations of acute-phase response markers and without signs of renal disease.

An association between autoinflammatory syndromes

and autoimmune diseases has been investigated. The TNFRSF1A R92Q mutation is frequently observed in patients with RA⁶ and has been identified as a new susceptibility factor for MS, while the D12E exchange has not been described to date in patients with MS^{7,8}. Four of the mutation carriers were diagnosed with RRMS and 1 patient had additional RA, supporting the view that TNFRSF1A mutations exert a proinflammatory role in autoimmune diseases, although the exact pathophysiological mechanisms are not completely understood. A few of the mutations interfere with the shedding of the TNF receptor 1 from the cell membrane into the extracellular compartment, thereby reducing its ability to neutralize TNF- α by binding^{5,9,10}. Other genetic defects alter the 3-dimensional structure of the protein, resulting in misfolding of the extracellular receptor domain and in retention of the mutated TNFR1 in the endoplasmic reticulum^{11,12}. Recently, it has also been shown that TRAPS mutants with major structural changes increase the mitochondrial production of reactive oxygen species, leading to sustained mitogen-activated protein kinase activity and thereby enhancing innate immune responses¹³. This could be an important common pathophysiological pathway in TRAPS patients with additional

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2013. All rights reserved.

autoimmune diseases. However, because the TNFRSF1A D12E substitution has not been investigated in detail to date and PolyPhen-2 analysis predicts that it is a benign mutation, it remains unclear how this exchange contributes to the observed clinical phenotypes.

We have identified 8 subjects carrying the TNFRSF1A D12E substitution who displayed TRAPS-related symptoms. The mutation may enhance the inflammatory response, thereby contributing to the manifestation of MS and RA in 4 mutation carriers. This cohort thus highlights the close pathophysiological relationship between TNF signaling, TRAPS, and autoimmune diseases such as RA and MS.

ACKNOWLEDGMENT

Sabine Pitter provided excellent technical assistance.

REFERENCES

- Kuempfel T, Hoffmann LA, Pellkofer H, Pollmann W, Feneberg W, Hohlfeld R, et al. Multiple sclerosis and the TNFRSF1A R92Q mutation: Clinical characteristics of 21 cases. Neurology 2008;71:1812-20.
- Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:1748-57.
- Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I. INFEVERS: The registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003; 31:282-5
- Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003;48:2632-44.
- D'Osualdo A, Ferlito F, Prigione I, Obici L, Meini A, Zulian F, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: Pathogenetic and clinical implications. Arthritis Rheum 2006;54:998-1008.

- Dieude P, Goossens M, Cornelis F, Michou L, Bardin T, Tchernitchko DO. The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows no evidence for association or linkage with the disease. Ann Rheum Dis 2007:66:1113-5.
- De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;41:776-82.
- Kuempfel T, Hoffmann LA, Ruebsamen H, Pollmann W, Feneberg W, Hohlfeld R, et al. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum 2007;56:2774-83.
- Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA, et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: Differences between cell types. Arthritis Rheum 2004;50:2651-9.
- Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, Belohradsky BH, et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008;67:1292-8.
- Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006;108:1320-7.
- Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I, et al. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006; 54:2674-87
- Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011;208:519-33.